RESEARCH COMMUNICATIONS OF THE 28th ECVIM-CA CONGRESS

A double‐blinded, placebo‐controlled trial was performed using 24 healthy dogs that were randomized to 1 of 4 treatment groups: placebo, prednisone 2 mg/kg/d, clopidogrel 2‐3 mg/kg/d, or combined prednisone/clopidogrel therapy PO for 28 days. Complete blood counts, manual platelet counts, PFA‐100® closure times (collagen/ADP), and area under the curve (AUC) for Multiplate® whole‐blood aggregometry (ADPtest) were determined at baseline, day 14, and day 28. Platelet reactivity was categorized as controlled if closure times increased ≥30% compared to baseline or AUC was ≤46U; control based on AUC was subcategorized into adequate (19‐46U) and excess (<19U) control. Closure times, AUC, platelet reactivity control, and degree of control were compared among groups using mixed model, split‐plot repeated measures ANOVAs, generalized estimating equation proportional odds models, and Fisher's exact tests as appropriate. P<0.05 was considered significant.